Lexaria Biosciences Says On Aug. 24 Co Received A Letter From NASDAQ Confirming The Cure Of NASDAQ Bid Price Deficiency
Portfolio Pulse from Benzinga Newsdesk
Lexaria Biosciences has received a letter from NASDAQ confirming the cure of NASDAQ bid price deficiency, according to an SEC filing.
August 28, 2023 | 6:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexaria Biosciences has resolved its NASDAQ bid price deficiency issue, which could potentially improve investor confidence.
The resolution of the NASDAQ bid price deficiency issue indicates that Lexaria Biosciences is now in compliance with NASDAQ's listing requirements. This could potentially improve investor confidence in the company and have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100